La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Evofem Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Evofem Biosciences..

Evofem Biosciences (OTC:EVFM) Azioni, Catena delle Opzioni

Evofem Biosciences

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc.

Evofem Biosciences Inc

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is looking for Q4 Adj EPS of $2.50-$2.70 vs $2.69 analyst estimate. sees sales of $860.000 million-$900.000 million vs $888.62 million analyst estimate.

News

Guidance

Fabrinet Sees Q4 Adj EPS $2.50-$2.70 vs $2.69 Est; Sees Sales $860.000M-$900.000M vs $888.62M Est

Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) affirms FY2025 Adj EPS guidance from $0.42-$0.46 to $0.42-$0.46 vs $0.45 analyst estimate. Affirms FY2025 sales outlook from $415.00 million-$425.00 million to $415.00 million-$425.00 million vs $420.67 million estimate.

CERT

Certara Affirms FY2025 Adj EPS Guidance of $0.42-$0.46 vs $0.45 Est; Affirms FY2025 Sales Guidance of $415.00M-$425.00M vs $420.67M Est

Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced that Sarah Wells, Chief Financial Officer ("CFO"), has resigned, effective May 14, 2025, to pursue other opportunities. Spruce expects to appoint an interim CFO prior to Wells departing. The Company is undertaking a search to fill the CFO position on a permanent basis.

Management

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Holding CFO Sarah Wells Resigns, Effective May 14, 2025

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) raises FY2025 GAAP EPS guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 analyst estimate..

Clorox Raises FY2025 GAAP EPS Guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 Est

Boise Cascade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCC#NYSE">BCC</a>) reported quarterly earnings of $1.06 per share which missed the analyst consensus estimate of $1.28 by 17.19 percent. This is a 59.39 percent decrease over earnings of $2.61 per share from the same period last year. The company reported quarterly sales of $1.54 billion which beat the analyst consensus estimate of $1.52 billion by 1.29 percent. This is a 6.63 percent decrease over sales of $1.65 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Boise Cascade Q1 EPS $1.06 Misses $1.28 Estimate, Sales $1.54B Beat $1.52B Estimate

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) affirms FY2025 Adj EPS guidance from $6.95-$7.35 to $6.95-$7.35 vs $7.12 analyst estimate. Narrows FY2025 sales outlook from $7.02 billion-$7.24 billion to $7.02 billion-$7.09 billion vs $7.10 billion estimate.

Clorox Affirms FY2025 Adj EPS Guidance of $6.95-$7.35 vs $7.12 Est; Narrows FY2025 Sales Guidance from $7.02B-$7.24B to $7.02B-$7.09B vs $7.10B Est

Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 40 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $106.00 million which beat the analyst consensus estimate of $104.88 million by 1.07 percent. This is a 9.67 percent increase over sales of $96.65 million the same period last year.

Certara Q1 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $106.00M Beat $104.88M Estimate

Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 61.54 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $323.34 million which beat the analyst consensus estimate of $321.00 million by 0.73 percent. This is a 3.28 percent increase over sales of $313.07 million the same period last year.

CRD/B

Crawford & Company Common Stock Q1 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $323.34M Beat $321.00M Estimate

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) reported quarterly earnings of $2.25 per share which missed the analyst consensus estimate of $2.49 by 9.64 percent. This is a 5.86 percent decrease over earnings of $2.39 per share from the same period last year. The company reported quarterly sales of $871.80 million which beat the analyst consensus estimate of $856.62 million by 1.77 percent. This is a 19.17 percent increase over sales of $731.53 million the same period last year.

Fabrinet Q3 Adj. EPS $2.25 Misses $2.49 Estimate, Sales $871.80M Beat $856.62M Estimate

Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.56 by 12.5 percent. This is a 14.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $461.58 million which beat the analyst consensus estimate of $452.13 million by 2.09 percent. This is a 5.78 percent increase over sales of $436.38 million the same period last year.

Vornado Realty Q1 FFO $0.63 Beats $0.56 Estimate, Sales $461.58M Beat $452.13M Estimate

SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.26 by 88.46 percent. This is unchanged from the same period last year. The company reported quarterly sales of $727.30 million which beat the analyst consensus estimate of $692.00 million by 5.10 percent. This is a 6.10 percent increase over sales of $685.50 million the same period last year.

SPNT

SiriusPoint Q1 GAAP EPS $0.49 Beats $0.26 Estimate, Sales $727.30M Beat $692.00M Estimate

WIIM

UPWK

Upwork shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) affirms FY2025 GAAP EPS guidance from $5.35 to $5.35 vs $5.34 analyst estimate. Affirms FY2025 sales outlook from $1.51 billion to $1.51 billion vs $1.51 billion estimate.

IPAR

Interparfums Affirms FY2025 GAAP EPS Guidance of $5.35 vs $5.34 Est; Affirms FY2025 Sales Guidance of $1.51B vs $1.51B Est

ONE Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGS#NYSE">OGS</a>) affirms FY2025 GAAP EPS guidance from $4.20-$4.32 to $4.20-$4.32 vs $4.27 analyst estimate..

ONE Gas Affirms FY2025 GAAP EPS Guidance of $4.20-$4.32 vs $4.27 Est

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.36 by 2.78 percent. This is unchanged from the same period last year. The company reported quarterly sales of $183.54 million which beat the analyst consensus estimate of $178.38 million by 2.89 percent. This is a 10.07 percent increase over sales of $166.75 million the same period last year.

SBRA

Sabra Health Care REIT Q1 FFO $0.35 Misses $0.36 Estimate, Sales $183.54M Beat $178.38M Estimate

ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.51) by 17.65 percent. This is a 13.51 percent decrease over losses of $(0.37) per share from the same period last year.

ORIC

ORIC Pharmaceuticals Q1 EPS $(0.42) Beats $(0.51) Estimate

MYPS

PLAYSTUDIOS Affirms FY2025 Sales Guidance of $250.00M-$270.00M vs $257.31M Est

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) affirms FY2025 Adj EPS guidance from $1.94-$2.18 to $1.94-$2.18 vs $2.12 analyst estimate..

Williams Companies Affirms FY2025 Adj EPS Guidance of $1.94-$2.18 vs $2.12 Est

ICHR

Ichor Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates.

CRBG

Corebridge Financial Q1 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $4.74B Miss $5.28B Estimate

Press Releases

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Small Cap

Evofem Biosciences to Present at Emerging Growth Conference

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Comments

Evofem Biosciences

Evofem Biosciences (EVFM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO